1213591-14-0

Basic information

• Product Name: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride
• CAS NO: 1213591-14-0
• Molecular Weight: 229.109
• Mol File: 1213591-14-0.mol

Chemical Properties

• CAS DataBase Reference: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(1213591-14-0)
• EPA Substance Registry System: (S)-6-chloro-4-cyano-2,3-dihydro-1H-inden-2-aminium chloride(1213591-14-0)

Safety Data

• Hazardous Substances Data: 1213591-14-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Clonidine is used as an antihypertensive agent for the treatment of high blood pressure. Its mechanism of action involves the stimulation of alpha-2 adrenergic receptors, leading to a decrease in blood pressure and providing relief from hypertension-related symptoms.
Used in Neurology:
In the field of neurology, Clonidine is utilized in the treatment of attention deficit hyperactivity disorder (ADHD). It helps in managing the symptoms of ADHD by modulating the overstimulation of the sympathetic nervous system, which is often associated with the disorder.
Used in Off-Label Treatments:
Clonidine is also used off-label for managing symptoms of opioid withdrawal, menopausal flushing, and anxiety. Its ability to reduce the activity of the sympathetic nervous system makes it a viable option for these conditions, although it is essential to consult a doctor before using it for these purposes.
Used in Drug Formulation:
Clonidine is available in both oral and transdermal formulations, offering patients flexibility in terms of administration and dosage. The transdermal patches provide a slow and steady release of the medication, which can be beneficial for maintaining consistent blood pressure levels throughout the day.

Upstream product

• 64278-20-2 1,1-Dimethyl-indan-5-carbonitrile 
• 1026500-01-5 3-Bromo-1,1-dimethyl-indan-5-carbonitrile 
• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 56461-20-2 1-oxoindane-4-carboxylic acid 
• 17640-21-0 isopropyl methoxyacetate 
• 34698-41-4 2,3-dihydro-1H-inden-1-amine 
• 776-79-4 2-(2-carboxyethyl)benzoic acid 
• 83-33-0 inden-1-one 
• 447-53-0 1,2-Dihydronaphthalene 
• 91-20-3 naphthalene 
• 612-17-9 1,4-dihydronaphthalene 
• 817-95-8 ethyl 2-ethoxyethanoate 
• 934765-76-1 1,1-dimethylethyl (5-cyano-2,3-dihydro-1H-inden-2-yl)carbamate 
• 124369-43-3 1,1-Dimethyl-1H-indene-5-carbonitrile 

Downstream Products

• 1027799-41-2 4-bromo-N-(5-cyano-2,3-dihydro-1H-inden-2-yl)-2-(trifluoromethyl)benzenesulfonamide 
• 1213099-69-4 (S)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile 
• 1107650-45-2 (R)-3-amino-2,2-dimethyl-2,3-dihydro-1H-indene-5-carbonitrile 
• 1107650-46-3 (S)-3-amino-2,2-dimethyl-2,3-dihydro-1H-indene-5-carbonitrile 
• 1306760-86-0 5-(3-{(1S)-1-[(2-hydroxyethyl)amino]-2,3-dihydro-1H-inden-4-yl}-1,2,4-oxadiazol-5-yl)-2-[(propan-2-yl)oxy]benzonitrile 
• 1306763-31-4 tert-butyl N-[(1S)-4-cyano-2,3-dihydro-1H-inden-1-yl]carbamate 
• 1306763-30-3 (R)-tert-butyl 4-cyano-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1213203-23-6 (R)-(1-amino-2,3-dihydro-1H-indene-1-yl)-4-carbonitrile 
• 1307231-06-6 (R)-tert-butyl 4-(5-(3,4-diethoxybenzyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1306763-41-6 (R)-tert-butyl 2-(tert-butyldimethylsilyloxy)ethyl(4-cyano-2,3-dihydro-1H-inden-1-yl)carbamate 

Relevant articles and documents

Preparation method of ozanimod intermediate

The invention discloses a preparation method of an ozanimod intermediate, which comprises the following four steps: synthesis of 4-cyanoindene oxime, synthesis of N-(4-cyano-3H-indene-1-yl)-acetamide, synthesis of N-(4-cyanoindan-1-yl)-acetamide, and synthesis of (S)-1-amino-2, 3-dihydro-1H-indene-4-formonitrile. The method has the advantages of easily available and cheap raw materials, mild reaction conditions, free of dangerous intermediates and unstable intermediates, and high chiral selectivity.

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

SUBSTITUTED AMINO-PYRIMIDINES

The invention provides novel compounds having the general formula (I), wherein R1, R2, and R3 are as defined herein, compositions including the compounds and methods of using the compounds.

AMINO-PYRIMIDINE CYCLO-AMIDES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3 and n are as defined herein, compositions including the compounds and methods of using the compounds.

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1PR), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills’ catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.

AMINO-PYRIMIDINE AMIDES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein, compositions including the compounds and methods of using the compounds.

A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-1-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE

The present invention relates to an improved process for preparation of Ozanimod (I) or pharmaceutically acceptable salts thereof. The present invention also relates to an improved process for preparation of (S)-l-amino-2,3-dihydro- 1H-indene-4-carbonitrile (II) or its optically active acid salts.

PD-1/PD-L1 INHIBITORS

Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

IMPROVED PROCESS FOR PREPARING OZANIMOD

The presented invention relates to a process for preparation of compound of formula (1) or a salt thereof (i.e.) ozanimod : (1). The invention also relates to intermediates used in the process.

PROCESS FOR THE PREPARATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST

Industrially viable and advantageous processes for the preparation of Ozanimod are described. The invention also discloses the intermediates obtained in the process.